Drugs / AMG 747
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01568229 | May 2012 → Jun 2013 | schizophrenia | Amgen | Terminated | Missed primary |
| Phase 2 | NCT01568216 | May 2012 → Jun 2013 | schizophrenia | Amgen | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 747 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01568216 ↗ |
| Action | Inhibit | “To determine the safety and efficacy of AMG 747, an oral inhibitor of glycine transporter type-1 (GlyT1), as an add-on to antipsychotic therapy in clinically stable people with...” PMID 27789188 ↗ Oct 2016 |
| Route | Oral | “Adults diagnosed with schizophrenia stabilized on antipsychotic medication randomized (2:2:2:3) to orally receive daily AMG 747 (5mg, 15mg, or 40mg) or placebo.” PMID 27789188 ↗ Oct 2016 |